DENVER, Oct. 14, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is strengthening its boardroom, while its clinical-development progress seeks to advance treatments for some of the most difficult cancers to treat. The clinical-stage biopharmaceutical company appointed Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, to its Board of Directors effective October 9, 2026, adding more than three decades of international banking, governance and business leadership experience.

“Ali’s appointment strengthens our Board as we advance our clinical programs and build our presence in Abu Dhabi,” said Amir Heshmatpour, NeOnc’s executive chairman, president and chief executive officer. Alabedin succeeds Dr. Steven L. Giannotta, who has stepped down from the board but will continue serving on NeOnc’s Scientific Advisory Board, preserving his scientific contribution while the company adds financial and international-growth expertise.

The appointment comes as NeOnc pursues a broader development strategy for its NEO drug platform, designed to address the challenge of delivering therapies across the blood-brain barrier. One of the company’s central programs, NEO212, has completed Phase 1 dose escalation and is advancing toward Phase 2. The Department of Health – Abu Dhabi granted investigational new drug authorization supporting development in the UAE, subject to required ethics approvals and other pre-enrollment conditions. That opens a potential route to regional clinical development, but it does not constitute marketing approval or confirm that patient enrollment has begun.

NeOnc also reported a series of recent corporate and clinical milestones. On August 12, the company announced positive topline results from its 24-patient NEO100 Phase 2a study, reporting six-month progression-free survival of 48.9% against a prespecified 20% benchmark and median overall survival of 26.09 months. On September 17, it announced the redemption of its outstanding Series A convertible preferred stock, a capital-structure development the company said eliminated the associated potential dilution without issuing common shares.

The next major dates on the calendar include November 17, 2026, when NeOnc announced an End-of-Phase 1 Type B meeting with the U.S. Food and Drug Administration regarding NEO212. The discussions are expected to address potential Phase 2 trial design, patient population, endpoints and regulatory pathways. The meeting is a key opportunity to obtain regulatory feedback. Further milestones to watch include UAE ethics clearance and confirmation of NEO212 trial readiness, potential follow-up FDA engagement on NEO100 after its Phase 2a results.

About 24/7 Market News

In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact [email protected] to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here . This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
[email protected]

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.